Abstract

Age-associated DNA methylation in blood cells convey information on health status. However, the mechanisms that drive these changes in circulating cells and their relationships to gene regulation are unknown. We identified age-associated DNA methylation sites in six purified blood borne immune cell types (naïve B, naïve CD4+ and CD8+ T cells, granulocytes, monocytes and NK cells) collected from healthy individuals interspersed over a wide age range. Of the thousands of age-associated sites, only 350 sites were differentially methylated in the same direction in all cell types and validated in an independent longitudinal cohort. Genes close to age-associated hypomethylated sites were enriched for collagen biosynthesis and complement cascade pathways, while genes close to hypermethylated sites mapped to neuronal pathways. In-silico analyses showed that in most cell types, the age-associated hypo- and hypermethylated sites were enriched for ARNT (HIF1β) and REST transcription factor motifs respectively, which are both master regulators of hypoxia response. To conclude, despite spatial heterogeneity, there is a commonality in the putative regulatory role with respect to transcription factor motifs and histone modifications at and around these sites. These features suggest that DNA methylation changes in healthy aging may be adaptive responses to fluctuations of oxygen availability.

Data availability

DNA methylation EPIC 850k data are available at GEO under accession number GSE184269

The following previously published data sets were used

Article and author information

Author details

  1. Roshni Roy

    Laboratory of Molecular Biology and Immunology, National Institute on Aging, Baltimore, United States
    Competing interests
    The authors declare that no competing interests exist.
  2. Pei-Lun Kuo

    Translational Gerontology Branch, National Institute on Aging, Baltimore, United States
    Competing interests
    The authors declare that no competing interests exist.
  3. Julián Candia

    Translational Gerontology Branch, National Institute on Aging, Baltimore, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-5793-8989
  4. Dimitra Sarantapoulou

    Laboratory of Molecular Biology and Immunology, National Institute on Aging, Baltimore, United States
    Competing interests
    The authors declare that no competing interests exist.
  5. Ceereena Ubaida-Mohien

    Translational Gerontology Branch, National Institute on Aging, Baltimore, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-4301-4758
  6. Dena Hernandez

    Laboratory of Neurogenetics, National Institute on Aging, Bethesda, United States
    Competing interests
    The authors declare that no competing interests exist.
  7. Mary Kaileh

    Laboratory of Molecular Biology and Immunology, National Institute on Aging, Baltimore, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-2314-312X
  8. Sampath Arepalli

    Laboratory of Neurogenetics, National Institute on Aging, Bethesda, United States
    Competing interests
    The authors declare that no competing interests exist.
  9. Amit Singh

    Laboratory of Molecular Biology and Immunology, National Institute on Aging, Baltimore, United States
    Competing interests
    The authors declare that no competing interests exist.
  10. Arsun Bektas

    Translational Gerontology Branch, National Institute on Aging, Baltimore, United States
    Competing interests
    The authors declare that no competing interests exist.
  11. Jaekwan Kim

    Laboratory of Molecular Biology and Immunology, National Institute on Aging, Baltimore, United States
    Competing interests
    The authors declare that no competing interests exist.
  12. Ann Z Moore

    Translational Gerontology Branch, National Institute on Aging, Baltimore, United States
    Competing interests
    The authors declare that no competing interests exist.
  13. Toshiko Tanaka

    Translational Gerontology Branch, National Institute on Aging, Baltimore, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-4161-3829
  14. Julia McKelvey

    Clinical Research Core, National Institute on Aging, Baltimore, United States
    Competing interests
    The authors declare that no competing interests exist.
  15. Linda Zukley

    Clinical Research Core, National Institute on Aging, Baltimore, United States
    Competing interests
    The authors declare that no competing interests exist.
  16. Cuong Nguyen

    Flow Cytometry Unit, National Institute on Aging, Baltimore, United States
    Competing interests
    The authors declare that no competing interests exist.
  17. Tonya Wallace

    Flow Cytometry Unit, National Institute on Aging, Baltimore, United States
    Competing interests
    The authors declare that no competing interests exist.
  18. Christopher Dunn

    Flow Cytometry Core, National Institute on Aging, Baltimore, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-7899-0110
  19. William Wood

    Laboratory of Genetics and Genomics, National Institute on Aging, Baltimore, United States
    Competing interests
    The authors declare that no competing interests exist.
  20. Yulan Piao

    Laboratory of Genetics and Genomics, National Institute on Aging, Baltimore, United States
    Competing interests
    The authors declare that no competing interests exist.
  21. Christopher Coletta

    Laboratory of Genetics and Genomics, National Institute on Aging, Baltimore, United States
    Competing interests
    The authors declare that no competing interests exist.
  22. Supriyo De

    Laboratory of Genetics and Genomics, National Institute on Aging, Baltimore, United States
    Competing interests
    The authors declare that no competing interests exist.
  23. Jyoti Sen

    Laboratory of Clinical Investigation, National Institute on Aging, Baltimore, United States
    Competing interests
    The authors declare that no competing interests exist.
  24. Nan-ping Weng

    Laboratory of Molecular Biology and Immunology, National Institute on Aging, Baltimore, United States
    Competing interests
    The authors declare that no competing interests exist.
  25. Ranjan Sen

    Laboratory of Molecular Biology and Immunology, National Institute on Aging, Baltimore, United States
    Competing interests
    The authors declare that no competing interests exist.
  26. Luigi Ferrucci

    Translational Gerentology Branch, National Institute on Aging, Baltimore, United States
    For correspondence
    ferruccilu@grc.nia.nih.gov
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-6273-1613

Funding

No external funding was received for this work.

Ethics

Human subjects: GESTALT study was approved by the institutional review board of the National Institutes of Health. Informed consent as well as the consent to publish the data collected was obtained from every participant in the study. Since the study of gene expression and epigenetic regulation are essential aims of GESTALT, all participants were required to consent to DNA/RNA testing and storage at all visits in order to participate in the study. the GESTALT IRB approval number is 15-AG-0063.

Copyright

This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.

Metrics

  • 1,464
    views
  • 207
    downloads
  • 6
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Roshni Roy
  2. Pei-Lun Kuo
  3. Julián Candia
  4. Dimitra Sarantapoulou
  5. Ceereena Ubaida-Mohien
  6. Dena Hernandez
  7. Mary Kaileh
  8. Sampath Arepalli
  9. Amit Singh
  10. Arsun Bektas
  11. Jaekwan Kim
  12. Ann Z Moore
  13. Toshiko Tanaka
  14. Julia McKelvey
  15. Linda Zukley
  16. Cuong Nguyen
  17. Tonya Wallace
  18. Christopher Dunn
  19. William Wood
  20. Yulan Piao
  21. Christopher Coletta
  22. Supriyo De
  23. Jyoti Sen
  24. Nan-ping Weng
  25. Ranjan Sen
  26. Luigi Ferrucci
(2023)
Epigenetic signature of human immune aging in the GESTALT study
eLife 12:e86136.
https://doi.org/10.7554/eLife.86136

Share this article

https://doi.org/10.7554/eLife.86136

Further reading

    1. Genetics and Genomics
    Yi Li, Long Gong ... Shangbang Gao
    Research Article

    Resistance to anthelmintics, particularly the macrocyclic lactone ivermectin (IVM), presents a substantial global challenge for parasite control. We found that the functional loss of an evolutionarily conserved E3 ubiquitin ligase, UBR-1, leads to IVM resistance in Caenorhabditis elegans. Multiple IVM-inhibiting activities, including viability, body size, pharyngeal pumping, and locomotion, were significantly ameliorated in various ubr-1 mutants. Interestingly, exogenous application of glutamate induces IVM resistance in wild-type animals. The sensitivity of all IVM-affected phenotypes of ubr-1 is restored by eliminating proteins associated with glutamate metabolism or signaling: GOT-1, a transaminase that converts aspartate to glutamate, and EAT-4, a vesicular glutamate transporter. We demonstrated that IVM-targeted GluCls (glutamate-gated chloride channels) are downregulated and that the IVM-mediated inhibition of serotonin-activated pharynx Ca2+ activity is diminished in ubr-1. Additionally, enhancing glutamate uptake in ubr-1 mutants through ceftriaxone completely restored their IVM sensitivity. Therefore, UBR-1 deficiency-mediated aberrant glutamate signaling leads to ivermectin resistance in C. elegans.

    1. Genetics and Genomics
    Minsoo Noh, Xiangguo Che ... Sihoon Lee
    Research Article

    Osteoporosis, characterized by reduced bone density and strength, increases fracture risk, pain, and limits mobility. Established therapies of parathyroid hormone (PTH) analogs effectively promote bone formation and reduce fractures in severe osteoporosis, but their use is limited by potential adverse effects. In the pursuit of safer osteoporosis treatments, we investigated R25CPTH, a PTH variant wherein the native arginine at position 25 is substituted by cysteine. These studies were prompted by our finding of high bone mineral density in a hypoparathyroidism patient with the R25C homozygous mutation, and we explored its effects on PTH type-1 receptor (PTH1R) signaling in cells and bone metabolism in mice. Our findings indicate that R25CPTH(1–84) forms dimers both intracellularly and extracellularly, and the synthetic dimeric peptide, R25CPTH(1–34), exhibits altered activity in PTH1R-mediated cyclic AMP (cAMP) response. Upon a single injection in mice, dimeric R25CPTH(1–34) induced acute calcemic and phosphaturic responses comparable to PTH(1–34). Furthermore, repeated daily injections increased calvarial bone thickness in intact mice and improved trabecular and cortical bone parameters in ovariectomized (OVX) mice, akin to PTH(1–34). The overall results reveal a capacity of a dimeric PTH peptide ligand to activate the PTH1R in vitro and in vivo as PTH, suggesting a potential path of therapeutic PTH analog development.